Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concurrent Nab-paclitaxel with IMRT for Stage III-IVa NPC
NCT06611150Phase 1Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of paclitaxel in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Primary endpoints: Maximum Tolerated Dose and Recommended Phase II Dose. Started Aug 2024; status: recruiting.
02
Drugs
paclitaxel
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06611150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06611150.